1.70
+0.05(+3.03%)
Currency In USD
| Previous Close | 1.65 |
| Open | 1.79 |
| Day High | 1.81 |
| Day Low | 1.67 |
| 52-Week High | 5.01 |
| 52-Week Low | 1.41 |
| Volume | 25,770 |
| Average Volume | 36,983 |
| Market Cap | 9.4M |
| PE | -0.73 |
| EPS | -2.34 |
| Moving Average 50 Days | 1.72 |
| Moving Average 200 Days | 2.73 |
| Change | 0.05 |
If you invested $1000 in Aprea Therapeutics, Inc. (APRE) since IPO date, it would be worth $4.15 as of July 03, 2025 at a share price of $1.7. Whereas If you bought $1000 worth of Aprea Therapeutics, Inc. (APRE) shares 5 years ago, it would be worth $2.43 as of July 03, 2025 at a share price of $1.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
GlobeNewswire Inc.
Jun 25, 2025 1:00 PM GMT
Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy Initial Phase 1 clinical update shows early disease control in first HPV+ patie
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
GlobeNewswire Inc.
Mar 31, 2025 12:30 PM GMT
ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI InhibitionDOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq:
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
GlobeNewswire Inc.
Mar 11, 2025 12:30 PM GMT
DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities w